Rights issue
Denna information finns även tillgänglig på Svenska
The Board of Directors of aXichem AB (publ) ("aXichem" or the "Company"), which is listed on the Nasdaq First North Growth Market (“Nasdaq First North”), has today, February 23, 2023, with the support of the authorization of the general meeting, resolved on a new share issue with pre-emptive rights for existing shareholders of approximately SEK 50 million before issue costs (the "Rights Issue").
The Rights Issue is covered to 70 percent by subscription and guarantee commitments. The Rights Issue is carried out to scale up operations in connection with the planned commercialization of aXiphen® in poultry feed and to repay part of the convertible loan entered in April 2022. The Board of Directors has also resolved on a new convertible loan from Formue Nord of approximately SEK 10.53 million.
Preliminary timetable for the Rights Issue
|
2 March 2023 |
Last day of trading including the right to participate in the Rights Issue |
|
3 March 2023 |
First day of trading excluding the right to participate in the Rights Issue |
|
3 March 2023 |
Publication of Prospectus (expected date) |
|
6 March 2023 |
Record date |
|
8 March – 22 March 2023 |
Subscription period |
|
8 March – 17 March 2023 |
Trading in subscription rights |
|
8 March 2023 |
Until the Rights Issue is registered with the Swedish Companies Registration Office - Trading in paid subscribed shares ("BTA") |
|
24 March 2023 |
Expected date for publication of results in the Rights Issue |
Prospectus
Full terms and conditions and instructions for the Rights Issue, as well as other information about the Company will be presented in the prospectus that the Company is expected to publish around March 3, 2023.